DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Caverject (Alprostadil) - Published Studies


Caverject Related Published Studies

Well-designed clinical trials related to Caverject (Alprostadil)

Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial. [2013]

[Clinical effects of alprostadil injection on acute kidney injury after cardiac surgical procedures]. [2010.08.24]

Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. [2010.06]

Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. [2009.02]

[Effects of alprostadil and ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass in pediatric patients with congenital heart diseases] [2008.11.11]

Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. [2007.10]

Effects of pentoxifylline and alprostadil on ocular hemodynamics in healthy humans. [2007.02]

[Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)] [2007]

An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. [2006.08]

Topical alprostadil (PGE1) for the treatment of female sexual arousal disorder: in-clinic evaluation of safety and efficacy. [2006.03]

[Reevaluation of protective effects of alprostadil on hepatic function in patients undergoing hepatectomy] [2005.09]

Retention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunction. [2005.01]

Treatment of ischemic ulcers of the lower limbs with alprostadil (prostaglandin E1). [2004.08]

Sildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled study. [2004.02]

Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon. [2004]

Efficacy and safety of topical alprostadil cream for the treatment of female sexual arousal disorder (FSAD): a double-blind, multicenter, randomized, and placebo-controlled clinical trial. [2003.10]

Intravenous alprostadil, an analog of prostaglandin E1, prevents thiamylal-fentanyl-induced bronchoconstriction in humans. [2003.08]

The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. [2003.02]

Comparison of a needle-free high-pressure injection system with needle-tipped injection of intracavernosal alprostadil for erectile dysfunction. [2002.12]

Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. [2002.12]

A synthetic prostaglandin E1 analog, alprostadil alfadex, relaxes sphincter of Oddi in humans. [2002.01]

A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. [2001.02]

Effect of intravenous iloprost and alprostadil (PGE1) on peripheral resistance during femoro-distal reconstructions. [2000.12]

Optimizing the therapeutic approach of transurethral alprostadil. [2000.07]

Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. [2000.01]

Intracavernosal versus intraurethral alprostadil: a prospective randomized study. [1999.05]

The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group. [1998.12]

Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. [1998.06]

Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. [1998.05]

Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. [1998.01]

Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil Investigators. [1997.11]

Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil Investigators. [1997.11]

Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. [1997.10]

Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. [1997.01.02]

A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. [1996.12]

A cost analysis of alprostadil in liver transplantation. [1996.06]

Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. [1996.04.04]

Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients. [1996.04]

Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction. [1996]

A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Alprostadil Study Group. [1995.11]

Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. [1995.09]

An alprostadil analogue and human gastric secretion. A double-blind placebo-controlled study of the effects of a capsule and tablet formulation. [1989.07]

An alprostadil analogue and human gastric secretion. A double-blind placebo-controlled study of the effects of a tablet and lyovial formulation. [1987.08]

Well-designed clinical trials possibly related to Caverject (Alprostadil)

The significance of natriuretic peptide in treatment of pulmonary hypertension after mitral valve replacement. [2014]

Early versus late rehabilitation of erectile function after nerve-sparing radical cystoprostatectomy: a prospective randomized study. [2011.07]

Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. [2011.06]

Changes in penile length after robot-assisted laparoscopic radical prostatectomy. [2011.01]

[Multicenter randomized, double-blind, placebo-controlled trial of prostaglandin E1 cream for female sexual arousal disorder]. [2010.12.18]

Feasability of a novel audio-video sexual stimulation system: an adjunct to the use of penile duplex Doppler ultrasonography for the investigation of erectile dysfunction. [2010.12]

Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. [2010.11]

Effects of intravenous prostaglandin E1 on pain and body temperature in patients with post-herpetic neuralgia. [2010.04]

Efficacy and safety of lubiprostone in patients with chronic constipation. [2010.04]

[Therapeutic effect of prostaglandin E1 on diabetic nephropathy: a one-year follow-up study]. [2010.03]

Prostaglandin E1 for preventing the progression of diabetic kidney disease. [2010]

Topical treatment of erectile dysfunction with prostaglandin E ethyl ester. [2009.12]

The effects of prostaglandin E1 on interleukin-6, pulmonary function and postoperative recovery in oesophagectomised patients. [2009.11]

Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study. [2009.11]

Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. [2009.08]

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. [2009.02.01]

Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. [2009.02]

The efficacy of prostaglandin E1 derivative in patients with lumbar spinal stenosis. [2009.01.15]

Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. [2009.01]

Improvement of microcirculation after percutaneous transluminal angioplasty in the lower limb with prostaglandin E1. [2009.01]

Vaginal versus oral misoprostol for second-trimester pregnancy termination: a randomized trial. [2008.11.01]

Single-dose lubiprostone along with split-dose PEG solution without dietary restrictions for bowel cleansing prior to colonoscopy: a randomized, double-blind, placebo-controlled trial. [2008.09]

Why a combined intracavernosal injection with trimix and oral sildenafil is reliable therapy in the ultrasonographic evaluation of erectile dysfunction. [2008.09]

Increased serum fractalkine in systemic sclerosis. Down-regulation by prostaglandin E1. [2008.07]

Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. [2008.06]

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. [2008.04]

Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation). [2008.01]

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. [2008.01]

Influence of low-dose polyunsaturated fatty acids supplementation on the inflammatory response of healthy adults. [2007.10]

Efficacy and safety of misoprostol in induction of labour in a Nigerian tertiary hospital. [2007.07]

Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. [2007.06.01]

Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. [2007.05]

Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. [2007.02]

Lipo-prostaglandin E1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes. [2006.12]

Intraamniotic ethacridine lactate instillation versus vaginal PGE1 in second trimester termination of pregnancy. [2006.06.01]

The effects of prostaglandin E-1 in patients with intermittent claudication. [2006.06]

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. [2006.05]

Prostaglandin E1 attenuates impairment of cellular immunity after cardiopulmonary bypass. [2006.04]

Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. [2006.04]

Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. [2006.03.01]

Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy--results of a randomized prospective study. [2006.03]

An investigation of misoprostol in the promotion of wound healing. [2006]

Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren's syndrome patients. [2005.12]

Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. [2005.12]

Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. [2005.12]

Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs. [2005.08]

Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension. [2005.08]

Therapeutic effect of lipoprostaglandin E1 on sudden hearing loss. [2005.07]

Priming effect of misoprostol on estrogen pretreated cervix in postmenopausal women. [2005.07]

A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. [2005.07]

Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates. [2005.06]

Effect of glutamine on water and sodium absorption in human jejunum at baseline and during PGE1-induced secretion. [2005.06]

Lipid peroxidation in IgA nephropathy and the effect of lipo-prostaglandin E1. [2005.05]

Effects of prostaglandin E1 on the progression of aristolochic acid nephropathy. [2005.03]

Second trimester abortion using isosorbide mononitrate in addition to gemeprost compared with gemeprost alone: a double-blind randomized, placebo-controlled multicenter trial. [2005.03]

Medical versus surgical abortion: comparing satisfaction and potential confounders in a partly randomized study. [2005.03]

Saturation with oxygen for ductal dependent congenital heart diseases before and after the prostaglandin therapy. [2005.02]

Medical versus surgical abortion efficacy, complications and leave of absence compared in a partly randomized study. [2004.11]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017